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Gregory L. Moneta, MD, Section EditorChlorhexidine-Alcohol Versus Povidone-Iodine for Surgical-Site Antisepsis
Darouiche RO, Wall MJ Jr, Itani KMF, et al. N Engl J Med 2010;362:18-26.
Conclusion: For clean-contaminated surgery, cleansing of the pa-
tient’s skin with chlorhexidine-alcohol reduces surgical-site infections com-
pared with cleansing with povidone-iodine.
Summary: There are 27 million operative procedures performed an-
nually in the United States (Infect Control Hosp Epidemiol 1999;20:250-
78). Surgical-site infections occur in 300,000-500,000 patients in the
United States each year (J Am Coll Surg 2008;206:814-9; JAMA 2005;294:
2035-42). There are recommendations by the Centers for Disease Control
and Prevention (CDC) to use 2% chlorhexidine preparations for preopera-
tive cleansing of sites for insertion of vascular catheters, but no CDC
recommendations have been put forth regarding antiseptics to prevent
surgical-site infection in surgical procedures.
This study compared the efficacy of povidone-iodine and chlorhexidine-
alcohol in preventing surgical-site infections in patients with clean-contaminated
operations in six university-affiliated hospitals. Patients were randomly as-
signed to preoperative skin preparation with chlorhexidine-alcohol scrub or
povidone-iodine scrub and paint. Surgical-site infection 30 days was the
primary outcome. Secondary outcomes included individual types of surgical-
site infection.
There were 849 patients (440 in the povidone-iodine group and 409 in
the chlorhexidine-alcohol group) that qualified for intention to treat analy-
sis. Surgical-site infection rates were lower in the chlorhexidine-alcohol
group than the povidone-iodine group (9.5% vs 16.1%; relative risk, 0.59;
95% confidence interval, 0.41-0.85; P  .004). With regard to secondary
end points, chlorhexidine-alcohol was more protective against surgical-site
infections than povidone-iodine for superficial incisional infections (4.2% vs
8.6%, P  .008) and deep incisional infections (1% vs 3%, P  .05). There
was no difference in protection against organ-space infections 4.4% vs 4.5%.
There were 813 patients who were in the study for 30 days and were subject
to a per protocol analysis. Overall results remain similar. No differences were
noted in adverse events in the two study groups.
Comment: In the accompanying editorial to this article, Dr Richard
Wenzel makes the observation that human beings have approximately 1013
total cells, with a total number of colonizing microbes per human being of
1014. Basically, bacteria have a 10:1 numerical advantage! The study indi-
cates that all infections at a specific anatomic site can be reduced with a
relatively inexpensive process. By substituting chlorhexidine-alcohol for
povidone-iodine, all we need to treat are 17 surgical patients with clean-
contaminated wounds to prevent 1 surgical-site infection. Of course, vascu-
lar surgical procedures fall primarily into the clean-wound category rather than
clean-contaminated, as studied here. Nevertheless, the weight of the available
literature with respect to chlorhexidine-alcohol vs povidone-iodine for surgical-
site antisepsis clearly indicates that chlorhexidine-alcohol is the preferred agent.
Duration and Magnitude of the Postoperative Risk of Venous Throm-
boembolism in Middle Aged Women: Prospective Cohort Study
Sweetland S, Green J, Liu B; The Million Women Study collaborators. BMJ
2009;339:b4583.
Conclusion: Risk of venous thromboembolism (VTE) is substantially
increased in the first 12 postoperative weeks. This varies considerably with
type of surgery.
Summary: Scotland and England have central databases of National
Health Service (NHS)-funded hospital admissions. Individually linked data
are available since 1981 in Scotland and since 1997 in England. The Million
Women’s Study is a population-based prospective study that recruited 1.3
million woman (mean age, 56 years) through the NHS breast-screening
program from 1996 to 2001. Participants in the Million Women’s Study are
electronically linked to inpatient and day case NHS hospital admissions. The
data can be used to track hospital admissions and outpatient surgery and
follow-up selective complications. In this report, woman who had an inpa-
tient or day case hospital admission for a surgical procedure were monitored
for any subsequent diagnosis of pulmonary embolism or deep vein throm-
bosis as reflected in a second inpatient or day case hospital admission or as an
underlying cause of death. There were 947,454 woman recruited between
1996 and 2001. During follow-up, there were 239,614 admissions for
surgery; 5419 were admitted for VTE, and 270 died from VTE.
Woman undergoing surgery were 70 times more likely to admitted
with VTE in the first 6 weeks after an inpatient operation (relative risk [RR],
69.1; 95% confidence interval [CI], 63.1-75.6) and 10 times more likely to
be admitted for VTE after a day case operation (RR, 9.6; 95% CI, 8.0-11.5).
From 7 to 12 weeks after surgery, RR was 19.6 (95% CI, 16.6-23.1) for aVTE admission after an inpatient procedure. The RR was 5.5 (95% CI,
4.3-7.0) for admission for VTE after an outpatient procedure. There were
2487 admissions for pulmonary embolism and 3529 admissions for deep
venous thrombosis. Risk patterns were no different for these two diagnoses.
The greatest risk for admission for VTE occurred 1 to 6 weeks after surgery
in patients undergoing hip or knee replacement (RR, 220.6; 95% CI,
187.8-259.2) or operations for cancer (RR, 91.6; 95% CI, 73.9-113.4).
Comment: This study indicates that the risk of postoperative VTE
peaks at about 3 weeks, but VTE risk is still substantial for 12 weeks
postoperatively. It is not surprising that risks are greatest after inpatient
surgery, but the risk after outpatient surgery was also impressive. The
patients in this study were all middle-aged women, but it seems extended
prophylaxes should be considered after many different types of operations in
patients with one or more risk factors for VTE.
Growth Rates of Small Abdominal Aortic Aneurysms Correlate with
Clinical Events
Thompson AR, Cooper JA, Ashton HA, et al. Br J Surg 2010;97:37-44.
Conclusions: There is a bimodal growth pattern of abdominal aortic
aneurysms (AAAs). AAA-related events are associated with growth rates of at
least 2 mm annually.
Summary: It is well known there is variation in AAA growth rate,
indicating that AAA expansion does not conform to simple mechanics of
Laplace’s Law. In the United Kingdom Small Aneurysm Trial, growth of
AAAs ranged from 1.0 to 6.1 mm/y (Circulation 2004;110:16-21).
Peripheral arterial disease and diabetes are known to be associated with
slowed AAA growth and smoking with more rapid growth. Elastin peptide,
a serum biomarker, appears to be associated with AAA expansion (Eur J Vasc
Endovasc Surg 2008;36:273-80). Expansion associations with hypercholes-
terolemia, sex, and hypertension are less clear, whereas doxycycline, statins,
and angiotensin-converting enzyme inhibitors may slow AAA growth.
Some have demonstrated an association between increased AAA growth
and rupture (J Vasc Surg 2003;37:280-4), whereas others have been unable to
demonstrate such a relationship (J Vasc Surg 2002;35:666-71). In this report,
the authors examine patterns of AAA growth and the relationship between
aneurysm growth and specific risk factors (mean arterial pressure, history of
hypertension, hypercholesterolemia, diabetes, smoking, ischemic heart disease,
and sex) and aneurysm-related events (surgery or death).
From 1984 to 2007, data for 1649 individuals with AAAs were
collected prospectively in the Chichester AAA screening program. Data
included serial aortic size measurements, blood pressure, risk factors for
arterial disease, and medications. The authors adjusted growth rates for risk
factor confounders using flexible hierarchical modeling. AAA growth distribu-
tion was analyzed using Silverman’s test of multimodality. There were 1231
individuals with more than one scan over a surveillance interval of at least 3
months. AAAs demonstrated a bimodal growth pattern, with nearly 50% of all
AAAs never progressing to surgery or rupture. Adjusted AAA growth rates2
mm annually predicted AAA related events (surgery or death).
Comment: Many believe the natural history of AAAs is inevitable
progressive dilatation until rupture occurs or the patient dies from other
causes. The data, however, indicate only 27.2% of monitored AAAs end up
requiring repair, and patterns of expansion may relate to clinical events. This
information, along with more sophisticated models of stress points on the
AAA wall, may eventually allow better selection of patients for AAA repair.
Perhaps someday there will be a cohort of patients, even with relatively large
AAAs, that can be safely observed. Such knowledge would result in increased
peace of mind for the patient and the physician as well as savings for the
health care system.
Median Arcuate Ligament Syndrome: Vascular Surgical Therapy and
Follow-up of 18 Patients
Grotemeyer D, Duran M, Iskandar F, et al. Lagenbecks Arch Surg 2009;
394:1085-92.
Conclusion: Open surgical therapy is safe and reliable for treatment of
median arcuate ligament syndrome.
Summary: Fixed stenosis and intermittent compression of the celiac
artery are both common. Median arcuate ligament syndrome is character-
ized by a combination of extrinsic compression of the celiac artery from
median arcuate ligament fibrous bands or ganglionic periaortic tissue, or
both, in combination with abdominal pain, nausea, vomiting, and nonin-
tentional weight loss. It is an infrequent diagnosis. The incidence of median
arcuate ligament syndrome is estimated at 2 per 100,000 patients and is said
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